AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 Nov 2020 07:00 AM
RNS
Calquence approved in the EU for CLL
06 Nov 2020 07:00 AM
RNS
Brilinta approved in the US in stroke
05 Nov 2020 07:15 AM
RNS
Lynparza approved in the EU for wider ovarian use
05 Nov 2020 07:10 AM
RNS
Lynparza approved in the EU for prostate cancer
05 Nov 2020 07:05 AM
RNS
Forxiga approved in the EU for heart failure
05 Nov 2020 07:00 AM
RNS
AZN: Year-to-date and Q3 2020 results
02 Nov 2020 03:00 PM
RNS
Total Voting Rights
30 Oct 2020 07:00 AM
RNS
Atacand to be divested in more than 70 countries
29 Oct 2020 07:00 AM
RNS
Directorate Change
28 Oct 2020 07:03 AM
RNS
Enhertu US Priority Review in gastric cancer
28 Oct 2020 07:00 AM
RNS
Forxiga CV outcomes benefit approved in China
20 Oct 2020 07:00 AM
RNS
Tagrisso adjuvant lung cancer US Priority Review
19 Oct 2020 07:00 AM
RNS
Forxiga HF receives positive CHMP opinion
19 Oct 2020 07:00 AM
RNS
Trixeo Aerosphere receives positive CHMP opinion
12 Oct 2020 07:00 AM
RNS
COVID-19 antibodies advance and get US funding
02 Oct 2020 07:00 AM
RNS
Farxiga granted US BTD in chronic kidney disease
01 Oct 2020 03:00 PM
RNS
Total Voting Rights
25 Sep 2020 07:00 AM
RNS
Directorate Change
21 Sep 2020 07:05 AM
RNS
Lynparza EU recommendation in prostate cancer
21 Sep 2020 07:00 AM
RNS
Lynparza EU recommendation in ovarian cancer
21 Sep 2020 07:00 AM
RNS
Tagrisso reduced early lung cancer brain recurrenc
10 Sep 2020 07:01 AM
RNS
AstraZeneca to list all US securities on Nasdaq
10 Sep 2020 07:00 AM
RNS
Fasenra PhIII OSTRO trial met co-primary endpoints
01 Sep 2020 03:00 PM
RNS
Total Voting Rights
01 Sep 2020 07:00 AM
RNS
Imfinzi approved in EU for small cell lung cancer
01 Sep 2020 07:00 AM
RNS
Farxiga reduces CKD progression and risk of death
25 Aug 2020 07:00 AM
RNS
Ph I trial begins for COVID-19 monoclonal antibody
21 Aug 2020 07:00 AM
RNS
Imfinzi approved in Japan for SCLC
18 Aug 2020 07:00 AM
RNS
Imfinzi US Priority Review; four-week, fixed dose
04 Aug 2020 07:00 AM
RNS
AstraZeneca prices a $3bn bond issue
03 Aug 2020 03:00 PM
RNS
Total Voting Rights
30 Jul 2020 07:25 AM
RNS
Tagrisso US BTD for EGFRm adjuvant lung cancer
30 Jul 2020 07:18 AM
RNS
AZN: H1 2020 results
29 Jul 2020 07:00 AM
RNS
Board Committee Changes
28 Jul 2020 07:00 AM
RNS
Farxiga DAPA-CKD trial met all endpoints
27 Jul 2020 07:10 AM
RNS
Calquence receives positive CHMP opinion for CLL
27 Jul 2020 07:05 AM
RNS
Imfinzi recommended for EU approval in SCLC
27 Jul 2020 07:00 AM
RNS
AstraZeneca enters collaboration in oncology
24 Jul 2020 07:00 AM
RNS
Breztri Aerosphere approved in the US for COPD
22 Jul 2020 03:00 PM
RNS
Holding(s) in Company
22 Jul 2020 03:00 PM
RNS
Holding(s) in Company
21 Jul 2020 03:00 PM
RNS
Holding(s) in Company
21 Jul 2020 03:00 PM
RNS
Holding(s) in Company
20 Jul 2020 02:41 PM
RNS
COVID-19 vaccine Phase I/II showed immune response
16 Jul 2020 07:00 AM
RNS
Director Declaration
09 Jul 2020 07:00 AM
RNS
Brilinta granted US FDA Priority Review for stroke
08 Jul 2020 07:00 AM
RNS
Lynparza approved in the EU for pancreatic cancer
01 Jul 2020 03:00 PM
RNS
Total Voting Rights
30 Jun 2020 03:00 PM
RNS
Director/PDMR Shareholding
30 Jun 2020 07:00 AM
RNS
Selumetinib granted Japan orphan drug designation

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings